Literature DB >> 19377984

Peptide aptamers for small molecule drug discovery.

Carine Bardou1, Christophe Borie, Marc Bickle, Brian B Rudkin, Pierre Colas.   

Abstract

Peptide aptamers have primarily been used as research tools to manipulate protein function and study regulatory networks. However, they also find multiple applications in therapeutic research, from target identification and validation to drug discovery. Because of their unbiased combinatorial nature, peptide aptamers interrogate the biological significance of numerous molecular surfaces on target proteins. Their use enables the identification and validation of some of these surfaces as interesting therapeutic targets to pursue. Peptide aptamers can subsequently be used to guide the discovery of small molecule drugs specific for these molecular surfaces.Here, we present a high-throughput screening assay that identifies small molecules that displace interactions between proteins and their cognate peptide aptamers. AptaScreen is a duplex yeast two-hybrid assay featuring two luciferase reporter genes. It can be performed in 96- or 384-well plates and can be fully automated.

Mesh:

Substances:

Year:  2009        PMID: 19377984     DOI: 10.1007/978-1-59745-557-2_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  A novel assay for the detection of anti-human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology.

Authors:  Julien Thibaut; Yves Mérieux; Dominique Rigal; Germain Gillet
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

2.  Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.

Authors:  Robert M Sharkey; Edmund A Rossi; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Biother Radiopharm       Date:  2010-02       Impact factor: 3.099

Review 3.  The eleven-year switch of peptide aptamers.

Authors:  Pierre Colas
Journal:  J Biol       Date:  2008

4.  Calcineurin A versus NS5A-TP2/HD domain containing 2: a case study of site-directed low-frequency random mutagenesis for dissecting target specificity of peptide aptamers.

Authors:  Silvia Dibenedetto; David Cluet; Pierre-Nicolas Stebe; Véronique Baumle; Jérémie Léault; Raphaël Terreux; Marc Bickle; Benoit D E Chassey; Ivan Mikaelian; Pierre Colas; Martin Spichty; Michele Zoli; Brian B Rudkin
Journal:  Mol Cell Proteomics       Date:  2013-04-10       Impact factor: 5.911

5.  A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope.

Authors:  Elena Canali; Angelo Bolchi; Gloria Spagnoli; Hanna Seitz; Ivonne Rubio; Thelma A Pertinhez; Martin Müller; Simone Ottonello
Journal:  Sci Rep       Date:  2014-04-22       Impact factor: 4.379

Review 6.  Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling.

Authors:  Andrea Conidi; Veronique van den Berghe; Danny Huylebroeck
Journal:  Int J Mol Sci       Date:  2013-03-26       Impact factor: 5.923

7.  The inhibition of stat5 by a Peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells.

Authors:  Axel Weber; Corina Borghouts; Christian Brendel; Richard Moriggl; Natalia Delis; Boris Brill; Vida Vafaizadeh; Bernd Groner
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-20

Review 8.  Synthetic biology for pharmaceutical drug discovery.

Authors:  Jean-Yves Trosset; Pablo Carbonell
Journal:  Drug Des Devel Ther       Date:  2015-12-03       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.